Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01861197

Enrollment

Registered

2013-05-23

Start date

2013-03-31

Completion date

Unknown

Last updated

2013-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Squamous NSCLC

Keywords

Efficacy, Dovitinib, Squamous NSCLC

Brief summary

Efficacy of Dovitinib for Squamous NSCLC.

Interventions

DRUGDovitinib

Dovitinib 500mg daily for 5 days on/ 2 day off until progression

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to No maximum

Healthy volunteers

Inclusion criteria

* histologically confirmed squamous NSCLC * Previously treated with one or two lines of chemotherapy * FGFR amplification (FISH \> 5 copies of genes) * 20 years or older * ECOG PS 0-2

Exclusion criteria

* active infection * uncontrolled brain metastasis * unstable angina or MI

Design outcomes

Primary

Measure	Time frame
response rate	6 months

Countries

South Korea

Contacts

Primary ContactMyung-Ju Ahn

silkahn@skku.edu822-3410-3459

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 10, 2026